Payu Raval, Qingqing Ding, Puneet Singh, Alaaeddin Alrohaibani, Hongxia Sun, Di Ai et al. HER2 status change in residual breast carcinoma after neoadjuvant HER2-targeted therapy in patients with HER2-positive breast cancer. // Breast Cancer Research and Treatment. – 2026. – DOI: 10.1007/s10549-026-08088-z. – URL: https://doi.org/10.1007/s10549-026-08088-z
Payu Raval, Qingqing Ding, Puneet Singh, Alaaeddin Alrohaibani, Hongxia Sun, Di Ai, Kerollos Nashat Wanis, Ming Zhao, Hui Chen, Vicente Valero, Mariana Chavez-MacGregor, & Aysegul Sahin (2026). HER2 status change in residual breast carcinoma after neoadjuvant HER2-targeted therapy in patients with HER2-positive breast cancer. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-026-08088-z
Payu Raval, et al. “HER2 status change in residual breast carcinoma after neoadjuvant HER2-targeted therapy in patients with HER2-positive breast cancer.” Breast Cancer Research and Treatment, 2026. doi:10.1007/s10549-026-08088-z.
@article{Raval2026,
title = {HER2 status change in residual breast carcinoma after neoadjuvant HER2-targeted therapy in patients with HER2-positive breast cancer},
author = {Raval, Payu and Ding, Qingqing and Singh, Puneet and Alrohaibani, Alaaeddin and Sun, Hongxia and Ai, Di and Wanis, Kerollos Nashat and Zhao, Ming and Chen, Hui and Valero, Vicente and Chavez-MacGregor, Mariana and Sahin, Aysegul},
journal = {Breast Cancer Research and Treatment},
year = {2026},
doi = {10.1007/s10549-026-08088-z},
url = {https://doi.org/10.1007/s10549-026-08088-z}
}